TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Pierre Fabre Pharma Norden AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
20,944
|
18,754
|
21,828 |
| Financial expenses |
14
|
31
|
52 |
| Earnings before taxes |
746
|
573
|
724 |
| EBITDA |
678
|
548
|
796 |
| Total assets |
16,276
|
14,128
|
11,710 |
| Current assets |
16,201
|
14,046
|
11,627 |
| Current liabilities |
13,573
|
11,948
|
9,440 |
| Equity capital |
2,703
|
2,180
|
2,270 |
| - share capital |
35
|
36
|
36 |
| Employees (average) |
13
|
16
|
15 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
16.6%
|
15.4%
|
19.4% |
| Turnover per employee |
1,611
|
1,172
|
1,455 |
| Profit as a percentage of turnover |
3.6%
|
3.1%
|
3.3% |
| Return on assets (ROA) |
4.7%
|
4.3%
|
6.6% |
| Current ratio |
119.4%
|
117.6%
|
123.2% |
| Return on equity (ROE) |
27.6%
|
26.3%
|
31.9% |
| Change turnover |
2,828
|
-3,138
|
3,155 |
| Change turnover % |
16%
|
-14%
|
17% |
| Chg. No. of employees |
-3
|
1
|
1 |
| Chg. No. of employees % |
-19%
|
7%
|
7% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.